Free tool
FAERS Monitor: Lotensin Hct
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020033 or its brand name (Lotensin Hct, Benazepril Hydrochloride, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.
Reports
447
Serious
265
59% of reports
Hospitalization
145
Death reported
27
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness30
- diarrhoea24
- nausea23
- headache21
- hypertension21
- pain19
- fatigue18
- blood glucose increased17
- dyspnoea17
- pain in extremity16
- vomiting16
- arthralgia15
- drug ineffective15
- anxiety14
- asthenia14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 19 |
| 2006 | 15 |
| 2007 | 11 |
| 2008 | 19 |
| 2009 | 21 |
| 2010 | 19 |
| 2011 | 18 |
| 2012 | 24 |
| 2013 | 16 |
| 2014 | 36 |
| 2015 | 25 |
| 2016 | 35 |
| 2017 | 24 |
| 2018 | 39 |
| 2019 | 32 |
| 2020 | 22 |
| 2021 | 13 |
| 2022 | 4 |
| 2023 | 10 |
| 2024 | 10 |
| 2025 | 12 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertensionSignal | 21 | 4.7 | 3.1 | 57 |
| blood glucose increasedSignal | 17 | 4.2 | 2.7 | 39 |
| dizzinessSignal | 30 | 2.8 | 2.0 | 35 |
| pain in extremitySignal | 16 | 2.6 | 1.6 | 14 |
| anxietySignal | 14 | 2.3 | 1.4 | 9 |
| asthenia | 14 | 1.8 | 1.0 | 4 |
| diarrhoea | 24 | 1.7 | 1.2 | 7 |
| arthralgia | 15 | 1.7 | 1.0 | 4 |
| vomiting | 16 | 1.6 | 1.0 | 3 |
| headache | 21 | 1.6 | 1.0 | 4 |
| pain | 19 | 1.5 | 0.9 | 2 |
| dyspnoea | 17 | 1.4 | 0.9 | 2 |
| nausea | 23 | 1.4 | 0.9 | 2 |
| fatigue | 18 | 1.1 | 0.7 | 0 |
| drug ineffective | 15 | 0.5 | 0.3 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.